Similarly, combining vitamin C (VitC) with cetuximab, an EGFR-targeting antibody, suppresses drug-resistant cell emergence, restricts CRC organoid growth, and delays acquired resistance development in CRC xenografts. Here, EGFR is linked to colorectal carcinoma.